ArticleCase reports in ophthalmology
Presentation and Course of Pachyvitelliform Maculopathy: A Case Series and Mini-Review.
Article in Case reports in ophthalmology. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Introduction: Pachyvitelliform maculopathy (PVM) is a novel phenotype within the spectrum of pachychoroid disorders featuring subretinal fluid and yellowish, hyperreflective, and hyperautofluorescent deposits. This study aimed to characterize PVM through multimodal imaging and evaluate therapeutic responses to guide clinical management. Case Presentations: This retrospective study analyzed patient records from 2020 to 2025 at two ophthalmic centers. PVM was diagnosed based on subretinal hyperreflective material on optical coherence tomography (OCT), hyperautofluorescence, and increased choroidal thickness (>350 μm). Macular neovascularization was excluded via OCT angiography, fluorescein angiography (FA), and OCT. Outcomes following half-dose photodynamic therapy (hd-PDT) and subthreshold micropulse laser (SML) were evaluated. Seven patients with PVM were identified. At baseline, visual acuity did not exceed 0.5 Snellen in any case. Two eyes received hd-PDT (including one treated with combined SML and PDT), four received SML exclusively, and one was managed with observation only. Improvement in best corrected visual acuity occurred in 2 cases. While significant morphological restoration was observed in two eyes, it was also accompanied by atrophy of the outer retinal layers and retinal pigment epithelium. Only one patient achieved significant functional improvement following hd-PDT. One patient demonstrated the progressive evolution of vitelliform-like lesions from a simple form of central serous chorioretinopathy (CSC) over 60 months in the absence of prompt treatment. Conclusions: PVM represents a diagnostic challenge, often necessitating multimodal imaging to reliably distinguish it from macular dystrophies. Further large-scale studies are required to better establish the efficacy of available therapeutic approaches. Nevertheless, treatment modalities commonly employed in the management of CSC, such as PDT and SML, currently remain among the most viable options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.